Detalles de la búsqueda
1.
Bempegaldesleukin plus Nivolumab in First-line Metastatic Urothelial Carcinoma: Results from PIVOT-02.
Eur Urol;
82(4): 365-373, 2022 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-35643589
2.
Treatment With Etirinotecan Pegol for Patients With Metastatic Breast Cancer and Brain Metastases: Final Results From the Phase 3 ATTAIN Randomized Clinical Trial.
JAMA Oncol;
8(7): 1047-1052, 2022 07 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-35552364
3.
Bempegaldesleukin plus nivolumab in first-line renal cell carcinoma: results from the PIVOT-02 study.
J Immunother Cancer;
10(4)2022 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-35444058
4.
Bempegaldesleukin Plus Nivolumab in First-Line Metastatic Melanoma.
J Clin Oncol;
39(26): 2914-2925, 2021 09 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-34255535
5.
Bempegaldesleukin (NKTR-214) plus Nivolumab in Patients with Advanced Solid Tumors: Phase I Dose-Escalation Study of Safety, Efficacy, and Immune Activation (PIVOT-02).
Cancer Discov;
10(8): 1158-1173, 2020 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-32439653
6.
NKTR-214 immunotherapy synergizes with radiotherapy to stimulate systemic CD8+ T cell responses capable of curing multi-focal cancer.
J Immunother Cancer;
8(1)2020 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-32457127
7.
Bempegaldesleukin selectively depletes intratumoral Tregs and potentiates T cell-mediated cancer therapy.
Nat Commun;
11(1): 661, 2020 01 31.
Artículo
en Inglés
| MEDLINE | ID: mdl-32005826
8.
Human Abuse Potential of Oral NKTR-181 in Recreational Opioid Users: A Randomized, Double-Blind, Crossover Study.
Pain Med;
21(2): e114-e126, 2020 02 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-31553457
9.
A First-in-Human Study and Biomarker Analysis of NKTR-214, a Novel IL2Rßγ-Biased Cytokine, in Patients with Advanced or Metastatic Solid Tumors.
Cancer Discov;
9(6): 711-721, 2019 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-30988166
10.
Change in Topoisomerase 1-Positive Circulating Tumor Cells Affects Overall Survival in Patients with Advanced Breast Cancer after Treatment with Etirinotecan Pegol.
Clin Cancer Res;
24(14): 3348-3357, 2018 07 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-29618616
11.
Integrated population pharmacokinetics of etirinotecan pegol and its four metabolites in cancer patients with solid tumors.
Cancer Chemother Pharmacol;
81(5): 897-909, 2018 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-29564497
12.
Randomized study of etirinotecan pegol versus irinotecan as second-line treatment for metastatic colorectal cancer.
Cancer Chemother Pharmacol;
80(6): 1161-1169, 2017 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-29043412
13.
Erratum to: Prolonged survival in patients with breast cancer and a history of brain metastases: results of a preplanned subgroup analysis from the randomized phase III BEACON trial.
Breast Cancer Res Treat;
166(1): 327-328, 2017 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-28884461
14.
Modeling the receptor pharmacology, pharmacokinetics, and pharmacodynamics of NKTR-214, a kinetically-controlled interleukin-2 (IL2) receptor agonist for cancer immunotherapy.
PLoS One;
12(7): e0179431, 2017.
Artículo
en Inglés
| MEDLINE | ID: mdl-28678791
15.
Prolonged survival in patients with breast cancer and a history of brain metastases: results of a preplanned subgroup analysis from the randomized phase III BEACON trial.
Breast Cancer Res Treat;
165(2): 329-341, 2017 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-28612225
16.
Health-related quality of life in patients with locally recurrent or metastatic breast cancer treated with etirinotecan pegol versus treatment of physician's choice: Results from the randomised phase III BEACON trial.
Eur J Cancer;
76: 205-215, 2017 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-28360015
17.
Etirinotecan pegol administration is associated with lower incidences of neutropenia compared to irinotecan administration.
Cancer Chemother Pharmacol;
79(1): 57-67, 2017 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-27904955
18.
Safety and tolerability of etirinotecan pegol in advanced breast cancer: analysis of the randomized, phase 3 BEACON trial.
Springerplus;
5(1): 1033, 2016.
Artículo
en Inglés
| MEDLINE | ID: mdl-27441152
19.
NKTR-214, an Engineered Cytokine with Biased IL2 Receptor Binding, Increased Tumor Exposure, and Marked Efficacy in Mouse Tumor Models.
Clin Cancer Res;
22(3): 680-90, 2016 Feb 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-26832745
20.
NKTR-102 Efficacy versus irinotecan in a mouse model of brain metastases of breast cancer.
BMC Cancer;
15: 685, 2015 Oct 13.
Artículo
en Inglés
| MEDLINE | ID: mdl-26463521